- Home
- GERN vs CII Comparison
GERN vs CII Comparison
Compare GERN & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GERN | CII |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | 229 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 878.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GERN | CII |
|---|---|---|
| Price | $1.55 | $21.11 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.17 | N/A |
| AVG Volume (30 Days) | ★ 17.1M | 75.7K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $15.20 |
| 52 Week High | $2.01 | $26.17 |
Technical Indicators
Market Signals| Indicator | GERN | CII |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 36.95 |
| Support Level | $1.24 | $20.27 |
| Resistance Level | $1.70 | $21.43 |
| Average True Range (ATR) | 0.10 | 0.46 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 37.50 | 0.00 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.